Develop your Biomarker strategy, Help identifying responders to ICI’s, Monitor changes in immune response in your clinical trials and conduct the development of companion diagnostic tests. HalioDx strong expertise and compliant capabilities & processes permits to successfully develop CDx tests for a co-registration to the FDA.
Test your research cohorts by analyzing expression of selected adaptive and suppressive immune genes in the tumor microenvironment and giving you the full support to generate and analyze data from different tumor tissues.
Use our immune-oncology IVD solutions IMMUNOSCORE® in Localized Colon Cancer and IMMUNOSCORE® IC in Non-Small Cell Lung Cancer and obtain reliable results with our sophisticated algorithm and/or our advanced image analysis pipeline.
Partner with a Company at the cutting edge of the innovation in the field of cancer diagnosis and participate to the adoption of novel assays for cancer patients worldwide. Distributors can be either commercial companies active in the field of pathology of cancer diagnosis solutions or private/public pathology laboratories acting as local reference centers to centralize the HalioDx diagnosis solutions in their territory.